undamentalytics Newsletter
Sign in

Bio-rad Laboratories, Inc. cash flow statement

In fiscal 2025, Bio-rad Laboratories, Inc.'s operations generated $532m of cash; it spent $158m on capital projects, leaving free cash flow of $375m. It returned $296m through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations325226263266169273186216104285458585669194375455532493
Depreciation and amortisation102109121130147150132143149138134139138137146152165—
Stock-based pay91011131415172023283642516161625860
Capital spending688810314310712111214111113099109134113157166158140
Free cash flow257137160124621527475−715635947653682218290375353
Free cash flow after stock pay248127149110491375755−3112832443548521157227317293
Share buybacks—00000003492810050216429204296133
Shares issued1013141111158114557−23————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BIO vs FTREBIO vs MEDPBIO vs QGEN

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Bio-rad Laboratories, Inc.'s SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Bio-rad Laboratories, Inc.